

# Publications

Prof. Dr. Tom Stargardt

---

## Peer-reviewed journal articles (accepted, online first & in print)

1. Grünwald F, Stargardt T (2024): Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market, *Health Economics*, <https://orcid.org/0000-0003-3954-0955>.
2. Brinkmann C, Stargardt T, Brouwer WBF (2024): From Health to Wellbeing: Towards a Monetary Valuation of a Wellbeing-Adjusted Life Year, in: *Value in Health*, <https://doi.org/10.1016/j.jval.2024.02.015>.
3. Bokemeyer B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, Urzica E, Hartmann P, Zemke J, Tappe U, Schreiber S, Steinkat N, Langbrandtner J, Hüppe A, Stargardt T (2024): Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study), *Alimentary Pharmacology & Therapeutics*, <https://doi.org/10.1111/apt.17926>.
4. Büssgen M, Stargardt T (2024): To merge or not to merge? The Impact of Mergers and Acquisitions on Corporate Success in the Pharmaceutical Industry, *Managerial and Decision Economics*, <https://doi.org/10.1002/mde.4129>.
5. Steiner I, Bokemeyer B, Stargardt T (2023): Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease, *European Journal of Health Economics*, <https://doi.org/10.1007/s10198-023-01603-9>.
6. Himmler S, van Exel J, Brouwer W, Neumann-Böhme S, Sabat I, Schreyögg J, Stargardt T, Barros PP, Torbica A (2023): Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemic, *European Journal for Health Economics*, <https://doi.org/10.1007/s10198-023-01604-8>.

## Peer-reviewed journal articles

7. Rech J, Birkner B, Edelmann E, Verheyen F, Schett G, Stargardt T (2024): Treatment patterns of individualized real-life tapering approaches based on shared decision making in rheumatoid arthritis, *Zeitschrift für Rheumatologie*, 83(2):142-150, <https://doi.org/10.1007/s00393-023-01380-z>.
8. Böhm AK, Steiner IM, Stargardt T (2023): Market Diffusion of Biosimilars in Off-Patent Biologic Drug Markets across Europe, *Health Policy*, 132, <https://doi.org/10.1016/j.healthpol.2023.104818>.
9. Neumann-Böhme S, Sabat I, Brinkmann C, Attema A, Stargardt T, Schreyögg J, Brouwer W: Jumping the queue. Willingness to pay for faster access to COVID-19 vaccines in seven

European countries, *Pharmacoeconomics*, 41(10): 1389-1402  
<https://doi.org/10.1007/s40273-023-01284-5>.

10. Bayindir EE, Messerle R, Stargardt T, Schreyögg J (2023): Socioeconomic Disparities In Mortality And Health Care Use During The COVID-19 Pandemic: Evidence From Germany, *Health Affairs*, 42(12):1715-1725, <https://doi.org/10.1377/hlthaff.2023.00714>.
11. Sabat I, Neumann-Böhme S, Barros PP, van Exel J, Brouwer W, Torbica A, Stargardt T, Schreyögg J (2023): Vaccine Hesitancy Comes in Waves: Longitudinal Evidence on Willingness to Vaccinate Against COVID-19 from Seven European Countries, *Vaccine*, 41(36):5304-5312, <https://doi.org/10.1016/j.vaccine.2023.07.017>.
12. Büssgen M, Stargardt T (2023): 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?, *Applied Health Economics and Health Policy*, 21(5): 751-759, <https://doi.org/10.1007/s40258-023-00815-7>.
13. Larrain N, Wang S, Stargardt T, Gröne O (2023): Cooperation Improvement in an Integrated Healthcare Network: A Social Network Analysis, *International Journal of Integrated Care*, 23(2):32, <https://doi.org/10.5334/ijic.6519>.
14. Büssgen M, Stargardt T (2023): Does HTA compromise access to pharmaceuticals? The impact of AMNOG on launch delay, *European Journal for Health Economics*, 24:437-451, <https://link.springer.com/article/10.1007/s10198-022-01484-4>.
15. Pott C, Frey S, Stargardt T (2023): Does prospective payment influence quality of care? A systematic review of the literature, *Social Science & Medicine*, 323:115812 <https://doi.org/10.1016/j.socscimed.2023.115812>.
16. Meggiolaro A, Blankart R, Stargardt T, Schreyögg J (2023): An econometric approach to aggregating multiple cardiovascular outcomes in German hospitals, *European Journal for Health Economics*, 24(5):785-802, <https://doi.org/10.1007/s10198-022-01509-y>.
17. Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T (2023): Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting, *Rheumatology*, 62(4):1476-1484, <https://doi.org/10.1093/rheumatology/keac472>.
18. König HH, Neumann-Böhme S, Sabat I, Schreyögg J, Torbica A, van Exel J, Barros P, Stargardt T, Hajek A (2023): Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic: Evidence from the European COVID Survey (ECOS), *Quality of Life Research*, <https://doi.org/10.1007/s11136-022-03334-5>.
19. Wang SY, Cantarelli P, Groene O, Stargardt T, Belle N (2023): Patient expectations do matter - experimental evidence on antibiotic prescribing decisions among hospital-based physicians, *Health Policy*, 128:11-17, <https://doi.org/10.1016/j.healthpol.2022.11.009>.
20. Böhm A, Schneider U, Stargardt T (2023): Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients, *Applied Health Economics and Health Policy*, 21(1): 109-118, <https://doi.org/10.1007/s40258-022-00760-x>.
21. Vadia R, Malyar N, Stargardt T (2023): Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia (CLTI) patients with rest-

- pain, *Journal of Vascular Surgery*, 77(1):299-308, <https://doi.org/10.1016/j.jvs.2022.07.007>.
22. Büssgen M, Stargardt T (2022): Changes in Launch Delay and Availability of Pharmaceuticals in 30 European Markets over the Past Two Decades, *BMC Health Services Research*, BMC Health Services Research, 22, 1457. <https://doi.org/10.1186/s12913-022-08866-7>.
  23. Hajek A, Neumann-Böhme S, Sabat I, Torbica A, Schreyögg J, Barros PP, Stargardt T, König HH (2022): Depression and anxiety in later COVID-19 waves across Europe: New evidence from the European Covid Survey (ECOS), *Psychiatry Research*, 317, <https://doi.org/10.1016/j.psychres.2022.114902>.
  24. Hofer F, Schreyögg J, Stargardt T (2022): Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany: evidence from the first three years, *PLOS ONE*, <https://doi.org/10.1371/journal.pone.0267952>.
  25. Hajek A, Sabat I, Neumann-Böhme S, Schreyögg J, Barros PP, Stargardt T, König HH (2022): Prevalence and determinants of probable depression and anxiety during the COVID-19 pandemic in seven countries: Longitudinal evidence from the European COvid Survey (ECOS), *Journal of Affective Disorders*, 299: 517-524, <https://doi.org/10.1016/j.jad.2021.12.029>.
  26. Böhm A, Schneider U, Aberle J, Stargardt T (2021): Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. *PLOS ONE*, <https://doi.org/10.1371/journal.pone.0250993>.
  27. Chandler T, Neumann-Böhme S, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Torbica A, Stargardt T (2021): Blood donation in times of crisis: early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries, *Vox Sanguinis*, 116(10):1031-1041, <https://doi.org/10.1111/vox.13103>.
  28. Varghese NE, Sabat I, Neuman-Böhme S, Schreyögg J, Stargardt T, Torbica A, van Exel J, Barros PP, Brouwer W (2021): Risk Communication during COVID-19: A Descriptive Study on Familiarity with, Adherence to and Trust in the WHO Preventive Measures, *PLOS ONE*, <https://doi.org/10.1371/journal.pone.0250872>.
  29. Pott C, Stargardt T, Schneider U, Frey S (2021): Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany?, *European Journal for Health Economics*, 22(1): 101-114, doi: 10.1007/s10198-020-01241-5.
  30. Vadia R, Stargardt T (2021): Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK, *Applied Health Economics and Health Policy*, 19(2): 243-252, doi: 10.1007/s40258-020-00610-8.
  31. Böhm AK, Jensen ML, Sørensen MR, Stargardt T (2020): Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study, *JMIR Mhealth Uhealth*, 8(11):e22212. doi:10.2196/22212.

32. Blankart KE, Stargardt T (2020): The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany, *Health Economics*, 29(S1): 63-82.
33. Sabat I, Neuman-Böhme S, Varghesec NE, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020): United but divided: policy responses and people's perceptions in the EU during the COVID-19 outbreak, *Health Policy*, 124(9):909-918.
34. Baumann M, Stargardt T, Frey S (2020): Cost-utility of internet-based cognitive behavioral therapy in unipolar depression: A Markov model simulation, *Applied Health Economics and Health Policy*, 18(4): 567-578.
35. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020): Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19, *European Journal for Health Economics*, 21(7): 977-982.
36. Birkner B, Rech J, Stargardt T (2020): Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis, *PLOS ONE* 15(1):e0226754, doi: 10.1371/journal.pone.0226754.
37. Chandler T, Hiller J, Peine S, Stargardt T (2020): Blood donation and donors: insights from a large German teaching hospital, *Vox Sanguinis*, 115(1):27-35.
38. Frey S., Stargardt T., Schneider U., Schreyögg J (2019): The economic burden of cystic fibrosis in Germany from a payer perspective, *Pharmacoeconomics*, 37(8):1029-1039.
39. Guhl D, Blankart K, Stargardt T (2019): Service quality and perceived customer value in community pharmacies, *Health Services Management Research*, 32(1): 36-48.
40. Hofer F, Kauczor HU, Stargardt T (2018): Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach, *Lung Cancer*, 124:189-198.
41. Fischer K, Koch T, Kostev K, Stargardt T (2018): The impact of physician-level drug budgets on prescribing behaviour, *European Journal for Health Economics*, 19(2): 213-222.
42. Blankart CB, Stargardt T (2017): Preferred supplier contracts in post-patent prescription drug markets, *Health Care Management Science*, 20(3):419-432.
43. Stargardt T, Eckmann C, Bouza E, Rossolini GM, Grossi PA (2018): Attitudes of physicians from 10 European countries on adherence and how treatment modalities in ABSSSI affect adherence: results from a Delphi survey, *European Journal of Clinical Microbiology & Infectious Diseases*, 37(9):1611-1618.
44. Achelrod D, Schreyögg J, Stargardt T (2017): Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort, *European Journal of Health Economics*, 18(7): 869-892.
45. Lauenroth V, Stargardt T (2017): Pharmaceutical Pricing in Germany: How is Value Determined within the Scope of AMNOG?, *Value in Health*, 20(7): 927-935.

46. Achelrod D, Welte T, Schreyögg J, Stargardt T (2016): Costs and Outcomes of the German Disease Management Programme (DMP) for Chronic Obstructive Pulmonary Disease (COPD) - A large population-based cohort study, *Health Policy*, 120(9): 1029-39.
47. Fischer K, Heisser T, Stargardt T (2016): Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia, *Health Policy*, 120(10):1115-20.
48. Hofer F, Achelrod D, Stargardt T (2016): Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, *Applied Health Economics and Health Policy*, 14(6): 691-701.
49. Fischer K, Stargardt T (2016): The diffusion of generics after patent expiry in Germany, *European Journal of Health Economics*. 17(8): 1027-40.
50. Frey S, Blankart CB, Stargardt T (2016): Economic burden and quality of life effects of chronic lymphocytic leukemia: A systematic review of the literature, *Pharmacoeconomics*. 34(5): 479-498.
51. Guhl D, Fischer K, Schneider U, Stargardt T (2016): Dispensing behaviour of pharmacies in prescription drug markets, *Health Policy*, 120(2):190-7.
52. Fischer K, Stargardt T (2014): Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions, *Medical Decision Making*, 34(8):1030-47.
53. Stargardt T, Schreyögg J, Kondofersky I (2014): Measuring the Relationship between Costs and Outcomes: the Example of Acute Myocardial Infarction in German Hospitals, *Health Economics*, 23(6):653-69.
54. Achelrod D, Blankart C, Linder R, Kodolitsch Y, Stargardt T (2014): The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study, *Orphanet Journal of Rare Diseases*; 9:90.
55. Achelrod D, Stargardt T (2014): Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias, *Applied Health Economics and Health Policy*, 12(2): 151-163.
56. Frey S, Linder R, Juckel G, Stargardt T (2014): Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia – a Markov model parameterized using administrative data from a German sickness fund, *European Journal of Health Economics*, 15(2):133-142.
57. Haas L, Stargardt T, Schreyoegg J, Schlösser R, Danzer G, Klapp B (2013): The trade-off between costs and quality of care in the treatment of psychosomatic patients with somatoform pain disorder, *Applied Health Economics and Health Policy*, 11(4):359-368.
58. Blankart R, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T (2013): Cost of illness and economic burden of chronic lymphocytic leukemia, *Orphanet Journal of Rare Diseases*, 8(1):32.

59. Vondoros S, Stargardt T (2013): Reforms in the Greek pharmaceutical market during the financial crisis, *Health Policy*, 109(1):1-6.
60. Frey S, Stargardt T (2012): Compliance and persistence measurement using administrative data from German sickness funds, *Pharmacotherapy*, 32(10): 880-889.
61. Stargardt T, Schreyögg J (2012): A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data, *Health Policy*, 105(2-3): 110-118.
62. Roll K, Stargardt T, Schreyögg J (2012): Effect of type of insurance and income on waiting time for outpatient care, *Geneva Papers on Risk and Insurance - Issues and Practice*, 37(4): 609-632.
63. Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA (2012): Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of schizophrenic patients in Germany, *Journal of Clinical Psychopharmacology*, 32(5): 602-607.
64. Haas L, Stargardt T, Schreyögg J (2012): Cost-effectiveness of open versus laparoscopic appendectomy in the US: a multilevel approach with propensity score matching, *European Journal of Health Economics*, 13(5): 549-60.
65. Bäuml M, Stargardt T, Schreyögg J, Busse R (2012): Cost-effectiveness of drug-eluting stents in AMI patients in Germany, *Applied Health Economics and Health Policy*, 10(4): 235-248.
66. Haas L, Stargardt T, Schreyögg J, Schlössel R, Danzer G, Klapp BF (2012): Introduction of DRG-based reimbursement in inpatient psychosomatics – An examination of cost homogeneity and cost predictors in the treatment of patients with eating disorders, *Journal of Psychosomatic Research*, 73(5): 383-90.
67. Schreyögg J, Stargardt T (2012): Gesundheitsökonomische Evaluation auf Grundlage von GKV-Routinedaten, *Bundesgesundheitsblatt*, 55: 668-676.
68. Haas L, Stargardt T, Schreyögg J, Schlösser R, Danzer G, Klapp BF (2012): Inpatient costs and predictors of costs in the psychosomatic treatment of anorexia nervosa, *International Journal of Eating Disorders*, 45(2): 214-21.
69. Stargardt T (2011): Modeling pharmaceutical prices in Germany as a function of competition and regulation, *Applied Economics*, 43(29): 4515-4526.
70. Schreyögg J, Stargardt T, Tiemann O (2011): Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching, *Health Economics*, 20(1): 85-100.
71. Blankart R, Stargardt T, Schreyögg J (2011): Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia, *Pharmacoeconomics*, 29(1): 63-82.

72. Roll K, Stargardt T, Schreyögg J (2011): Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich, *Das Gesundheitswesen*; 73(8): 504-514.
73. Drummond M, Jönsson B, Rutten F, Stargardt T (2011): Obtaining value for money from pharmaceuticals: a comparison of reference pricing with health technology assessment, *European Journal of Health Economics*, 12(3):263-271.
74. Stargardt T, Mavrogiorgou P, Gericke CA, Juckel G (2011): Effectiveness and costs of flupentixol compared to other first and second generation antipsychotics in the treatment of schizophrenia, *Psychopharmacology*, 216(4): 579-87.
75. Schreyögg J, Stargardt T (2010): The Trade-Off Between Costs and Outcomes: The Case of Acute Myocardial Infarction, *Health Services Research*, 45(6):1585-601.
76. Stargardt T (2010): The Impact of Reference Pricing on Switching Behaviour and Healthcare Utilisation: The Case of Statins in Germany, *European Journal of Health Economics*, 11(3): 267-277.
77. Schreyögg J, Weller J, Stargardt T, Herrmann K, Dechow T, Glatting G, Krause BJ, Reske SN, Buck AK (2010): Cost-effectiveness of Hybrid PET/CT Imaging for Staging Non-Small Cell Lung Cancer, *The Journal of Nuclear Medicine*, 51 (11):1668-1675.
78. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schwaiger M, Schreyögg J (2010): Economic Evaluation of PET and PET/CT in Oncology Evidence and Methodological Approaches, *The Journal of Nuclear Medicine*, 51(3):401-412.
79. Stargardt T, Gonder-Frederick L, Krobot K, Alexander C (2009): Fear of Hypoglycaemia: Defining a Minimum Clinically Important Difference, in *Health and Quality of Life Outcomes*, 7(91).
80. Marett L, Stargardt T, Mavros P, Alexander C (2009): Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain, in *Diabetes Obesity and Metabolism*, 11: 1138-1144.
81. Stargardt T, Alexander C, Yin D (2009): Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus, *Diabetes Obesity and Metabolism*, 11: 491-497.
82. Weinbrenner S, Assion H, Stargardt T, Busse R, Juckel G, Gericke C (2009): Antipsychotic prescription patterns for schizophrenic outpatients in Germany, *Pharmacopsychiatry*, 42(2): 66-71.
83. Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke C (2008): Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care: retrospective cohort study, *Journal of Mental Health Policy and Economics*, 10(2): 89-97.
84. Stargardt T (2008): Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries, *Health Economics*, 17(S1): 9-20.

85. Schreyögg J, Tiemann O, Stargardt T, Busse R (2008): Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories, *Health Economics*, 17(S1): 95-103.
86. Stargardt T, Schreyögg J, Busse R (2007): Pricing Behaviour of Pharmacies After Market Deregulation for OTC Drugs: The Case of Germany, *Health Policy*, 84(1): 30-38.
87. Stargardt T, Schreyögg J (2006): The Impact of Cross-reference Pricing on Pharmaceutical Prices – Manufacturers’ Pricing Strategies and Price Regulation, *Applied Health Economics and Health Policy*, 5(4): 235-247.
88. Schreyögg J, Stargardt T, Tiemann O, Busse R (2006): Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries, in: *Health Care Management Science*, 9(3):215-224.
89. Velasco-Garrido M, Schreyögg J, Stargardt T, Busse R (2006): Description des paniers de soins de neuf pays de l’Union européenne, in: *Revue française des Affaires sociales*, 2-3:32-90.
90. Stargardt T, Schreyögg J, Busse R (2005): Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen, in: *Das Gesundheitswesen*, 67(7):469-478.
91. Schreyögg J, Stargardt T, Velasco-Garrido M, Busse R (2005): Defining the benefit basket in nine European countries: Evidence from EU-HealthBASKET project, in: *European Journal of Health Economics*, 6(S1):2-10.
92. Busse R, Stargardt T, Schreyögg J (2005): Determining the benefit basket of the Statutory Health Insurance scheme in Germany: methodologies and criteria, in: *European Journal of Health Economics*, 6(S1):30-36.
93. Farhauer O, Borchardt K, Stargardt T (2004): Bürgerversicherung – Die Wirkung von Kopfprämien auf den Arbeitsmarkt, in: *Zeitschrift für die gesamte Versicherungswissenschaft*, 93(3):349-372.

## **Non peer-reviewed publications**

### **a) Books and book chapters**

1. Hofer F, Silva CF, Stargardt T, (2019): Healthcare Management – How to incentivize radiologists to facilitate value-based imaging, in: Silva CF, van Stackelberg O, Kauczor HU [eds.], *Value-based Radiology: A Practical Approach*, 67-74.
2. Stargardt T, Vondoros S (2014): Pharmaceutical Pricing and Reimbursement Regulation in Europe, in: Culyer JA [ed.], *Encyclopedia of Health Economics*, Vol 3. San Diego: Elsevier, 29-36.
3. Blankart R, Roll K, Heimeshoff M, Stargardt T, Schreyögg J (2014): Innovationsbedarf in der Gesundheitswirtschaft im Spiegel der Forschung, in: Bieber D, Geiger M [Hrsg.]:



Personenbezogene Dienstleistungen im Kontext komplexer Wertschöpfung, Springer, pp. 257-267.

4. Busse R, Schreyögg J, Stargardt T [Hrsg.] (2012): Management im Gesundheitswesen, Springer.
5. Stargardt T, Schreyögg J (2012): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 128-148.
6. Stargardt T, Tiemann O (2012): Personalmanagement im Gesundheitswesen – Einführung und methodische Grundlagen, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 336-338.
7. Schreyögg J, Stargardt T (2009): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, S. 122-140.
8. Schreyögg J, Stargardt T (2006): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, S. 123-141.

**b) Other publications**

1. Büssgen M, Stargardt T (2023): Reply to Comment to ‘Does HTA comprise access to pharmaceuticals? The impact of AMNOG on launch delay’, *European Journal for Health Economics*, 24, 1245-1248, <https://doi.org/10.1007/s10198-023-01611-9>.
2. Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P (2017): Therapie und Sekundärprävention der venösen Thromboembolie – Orale Antikoagulation im Wandel, *Deutsche Medizinische Wochenschrift* 142:1-8.
3. Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch S, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC (2016): Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern, *Herzschrittmachertherapie+ Elektrophysiologie*, 27(3): 295-306.
4. Vadoros S, Stargardt T (2013): Authors’ response to ‘Health service expenditures and efficiencies in Greece’, *Health Policy*, 111(2): 208-209.
5. Schreyögg J, Schultz C, Stargardt T, Busse R (2012): Focus on designing health care structures and services for rare diseases, *Health Policy*, 105(2-3): 107-109.
6. Roll K, Stargardt T, Schreyögg J (2012): Einfluss von Versichertenstatus und Einkommen auf die Wartezeit im ambulanten Bereich, *Monitor Versorgungsforschung*, 5(5): 27-29.
7. Stargardt T (2006) Focus on Germany, Reference Pricing, in: *Pharmaceutical Marketing Europe*, 3(1):32-34.

8. Farhauer O, Borchardt K, Stargardt T (2005): Bürgerversicherung \* Systematisierung und Bewertung der Reformvarianten, in: Wirtschaftswissenschaftliches Studium WiSt, 34(6):308-314.